- Home
- GRX vs ENTA Comparison
GRX vs ENTA Comparison
Compare GRX & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRX
- ENTA
- Stock Information
- Founded
- GRX 2007
- ENTA 1995
- Country
- GRX United States
- ENTA United States
- Employees
- GRX N/A
- ENTA N/A
- Industry
- GRX Finance/Investors Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- GRX Finance
- ENTA Health Care
- Exchange
- GRX Nasdaq
- ENTA Nasdaq
- Market Cap
- GRX 149.2M
- ENTA 154.0M
- IPO Year
- GRX N/A
- ENTA 2013
- Fundamental
- Price
- GRX N/A
- ENTA $5.10
- Analyst Decision
- GRX
- ENTA Buy
- Analyst Count
- GRX 0
- ENTA 4
- Target Price
- GRX N/A
- ENTA $17.25
- AVG Volume (30 Days)
- GRX 39.7K
- ENTA 266.6K
- Earning Date
- GRX 01-01-0001
- ENTA 05-05-2025
- Dividend Yield
- GRX 5.98%
- ENTA N/A
- EPS Growth
- GRX N/A
- ENTA N/A
- EPS
- GRX 0.26
- ENTA N/A
- Revenue
- GRX N/A
- ENTA $66,590,999.00
- Revenue This Year
- GRX N/A
- ENTA N/A
- Revenue Next Year
- GRX N/A
- ENTA N/A
- P/E Ratio
- GRX $38.50
- ENTA N/A
- Revenue Growth
- GRX N/A
- ENTA N/A
- 52 Week Low
- GRX $7.73
- ENTA $4.09
- 52 Week High
- GRX $10.40
- ENTA $17.24
- Technical
- Relative Strength Index (RSI)
- GRX 39.96
- ENTA 43.45
- Support Level
- GRX $9.36
- ENTA $4.55
- Resistance Level
- GRX $9.59
- ENTA $5.29
- Average True Range (ATR)
- GRX 0.29
- ENTA 0.47
- MACD
- GRX -0.02
- ENTA 0.06
- Stochastic Oscillator
- GRX 35.24
- ENTA 63.96
About GRX The Gabelli Healthcare & Wellness Trust of Beneficial Interest
Gabelli Healthcare & WellnessRx Trust operates as a diversified closed-end management investment company. The investment objective of the fund is the long-term growth of capital. The fund invests at least its assets in equity securities and income-producing securities of domestic and foreign companies in the healthcare and wellness industries. It invests in various sectors, of which Health Care Providers & Services, Food, Health Care Equipment and Supplies, and Pharmaceuticals account for the majority of the weightage.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.